Vaxcyte, Inc. — Director's Dealing 2022

May 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-05-09

Reporting Person: Eydelman Mikhail (SVP, Gen Counsel & Corp Sec)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-09	Stock Option (right to buy)	$21.41	A	225000	Acquired	2032-05-08	Common Stock (225000)	Direct

Footnotes

F1: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.